NCT00640146View on ClinicalTrials.gov

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 19, 2007

Primary Completion Date

January 21, 2009

Study Completion Date

January 21, 2009

Conditions

Opioid-induced Constipation

Interventions

DRUG

Methylnaltrexone bromide

Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.

DRUG

Placebo

Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.

Trial Locations (1)

10591

Progenics Pharmaceuticals, Inc, Tarrytown

All Listed Sponsors

collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Bausch Health Americas, Inc.

INDUSTRY

NCT00640146 - Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures | Biotech Hunter | Biotech Hunter